Autologous Endothelial Progenitor Cells Transplantation for Chronic Ischemic Stroke

Southern Medical University

Status and phase

Completed

Phase 2

Phase 1

Conditions

Stroke

Treatments

Drug: Intravenous stem cell transplantation

Study type

Interventional

Funder types

Other

Identifiers

NCT02605707

2011Y1-00033-6

Details and patient eligibility

About

Stroke is a frequently occurring and common diseases in nervous system,and most of the survivors will remain disorders of motor,sensory and cognition function.Stem cell transplantation provides a promising approach for rehabilitation. The main objective of this study is to evaluate the efficacy and safy of the transplantation of autologous endothelial progenitor cells in patients with chronic stroke.

Full description

Stroke is a frequently occurring and common diseases in nervous system,and most of the survivors will remain disorders of motor,sensory and cognition function.It will brought heavy burden to patients themselves,their family and society.Drugs,rehabilitation excise and hyperbaric oxygen will improve functions after acute stroke.However,in the chronic ischemic stroke,there was few methods to improve the functions.In recently research,stem cell will be a new methods to improve the neural function after through differentiate to nervous cells and secrete some neurotrophic factors to repair the damage. In this study, the investigators will assess the safety and feasibility of intracerebral transplantation of autologous endothelial progenitor cells in patients with chronic ischemic stroke. The neurological outcome will be determined after transplantation.

Enrollment

12 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged 18-80 chronic ischemia stroke or patients
With stroke history of more than 6 months, less than 60 months
NIHSS (NIH stroke scale) score of 7 or more points
Internal carotid artery territory infarction measured by MRI
Can be hospitalized and signed informed consent
With fewer effect by traditional post-stroke treatments or rehabilitations

Exclusion criteria

Lacunar infarction
Recurrent thrombotic diseases less than 6 months
Hemorrhage stroke,brain tumor or MRI show the occlusion is not in the middle cerebral artery territory
Pregnant women
Can't tolerate the test because of other disease, such as heart failure, liver failure, renal failure, abnormal blood coagulation, AIDS, combine other tumor or special condition
Penicillin anaphylaxis or some other drugs allergy
Autoimmune disease
Inaccessibility for follow up